Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone ( plus P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).

被引：0

作者：

Jayaram, Anuradha

Wingate, Anna

Sharabiani, Mansour Taghavi Azar

Wetterskog, Daniel

Calabro, Fabio

Barwell, Lorraine

Arlt, Weibke

Merseburger, Axel Stuart

Feyerabend, Susan

Berruti, Alfredo

Lefresne, Florence

Shen, Dong

Gormley, Michael

Kapoor, Gurpreet

Li, Weimin

Jones, Robert J.

Sternberg, Cora N.

Tombal, Bertrand F.

Attard, Gerhardt

机构：

[1] Inst Canc Res, Sutton, Surrey, England

[2] Royal Marsden NHS Trust Fdn, Sutton, Surrey, England

[3] Inst Canc Res, London, England

[4] Royal Marsden NHS Fdn Trust, London, England

[5] San Camillo Forlanini Hosp, Rome, Italy

[6] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[7] Univ Birmingham, Birmingham, W Midlands, England

[8] Univ Hosp Schleswig Holstein Campus Luebeck, Dept Urol, Lubeck, Germany

[9] Studienpraxis Urol, Nurtingen, Germany

[10] Univ Brescia, Spedali Civili Hosp, Med Oncol, Brescia, Italy

[11] Janssen Cilag, Paris, France

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] LabConnect LLC, Sci Operat, Seattle, WA USA

[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[15] San Camillo Forlanini Hosp, Rome, Italy

[16] Clin Univ St Luc, Brussels, Belgium

[17] Royal Marsden Hosp, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.5067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5067

引用

页数：2

共 50 条

[41] Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC)
Hahn, Andrew W.
Gill, David M.
Poole, Austin
Nussenzveig, Roberto H.
Wilson, Sara
Farnham, James M.
Stephenson, Robert A.
Cannon-Albright, Lisa A.
Maughan, Benjamin L.
Agarwal, Neeraj
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 726 - 729
[42] Randomized phase II study of docetaxel (D) plus abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial
Climent Duran, Miguel Angel
Font, Albert
Duran, Ignacio
Puente, Javier
Castellano, Daniel
Isabel Saez, M.
Mendez Vidal, Maria Jose Jose
Santander, Carmen
Arranz Arija, Jose Angel
Gonzalez del Alba, Aranzazu
Sanchez-Hernandez, Alfredo
Esteban, Emilio
Alonso Gordoa, Teresa
Maroto, Pablo
Lazaro Quintela, Martin Emilio
Cassinello, Javier
Perez Valderrama, Begona
Juan Fita, Maria Jose
Mellado, Begona
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[43] Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.
Posadas, Edwin M.
Chi, Kim N.
De Wit, Ronald
De Jonge, Maja J.
Attard, Gerhardt
Friedlander, Terence W.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[44] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Tagawa, Scott T.
Posadas, Edwin M.
Bruce, Justine Yang
Lim, Emerson A.
Petrylak, Daniel Peter
Peng, Weimin
Maul, Raymond Scott
Smit, Hans W.
Tran, Namphuong
Nanus, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
Massard, C.
Mateo, J.
Loriot, Y.
Pezaro, C.
Albiges, L.
Mehra, N.
Varga, A.
Bianchini, D.
Ryan, C. J.
Petrylak, D. P.
Attard, G.
Shen, L.
Fizazi, K.
de Bono, J.
ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
[46] A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).
Karzai, Fatima H.
Madan, Ravi Amrit
Apolo, Andrea Borghese
Parnes, Howard L.
Wright, John Joseph
Trepel, Jane B.
Beatson, Melony A.
Harold, Nancy
Couvillon, Anna
Steinberg, Seth M.
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[47] Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/prednisone (AA/P).
Giridhar, Karthik
Sosa, Carlos
Sicotte, Hugues
Wang, Liewei
Wang, Liguo
Sinnwell, Jason P.
Tan, Winston
Costello, Brian Addis
Quevedo, Fernando
Pitot, Henry C.
Bryce, Alan Haruo
Jimenez, Rafael E.
Weinshilboum, Richard M.
Dehm, Scott
Kalari, Krishna R.
Kohli, Manish
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[48] Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone
Ryan, C.
Efstathiou, E.
Smith, M.
Taplin, M.
Bubley, G.
Logothetis, C.
Kheoh, T.
Haqq, C.
Molina, A.
Small, E. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[49] Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA plus P).
Gotto, Geoffrey
Fradet, Vincent
Drachenberg, Darrel
Sabbagh, Robert
Rendon, Ricardo A.
Shayegan, Bobby
Danielson, Brita Lavender
Casey, Richard
Chan, Katherine
Camacho, Fernando
Zardan, Anousheh
Hew, Huong
Feifer, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[50] Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA plus P) for ≥ 4 years (yrs)
Carles, J.
Davis, I.
De Bono, J. S.
Fizazi, K.
Gerritsen, W.
Rathkopf, D. E.
Ryan, C. J.
Saad, F.
Steuber, T.
Wilding, G.
Park, Y. C.
Charnas, R.
De Porre, P.
Van Poppel, H.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →